Adoption of newly FDA-approved targeted immunomodulatory therapies by dermatologists: a cross-sectional analysis of Medicare Part D claims from 2013 to 2018
Crossref DOI link: https://doi.org/10.1007/s00403-022-02422-3
Published Online: 2022-10-25
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Dean, Owen
Tausk, Francisco
Singh, Partik
Text and Data Mining valid from 2022-10-25
Version of Record valid from 2022-10-25
Article History
Received: 6 May 2022
Revised: 6 May 2022
Accepted: 13 October 2022
First Online: 25 October 2022
Declarations
:
: The authors declared that they have no conflict of interest.